{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreidxqpsz5lufey7dzuihwj2jn7qhmrfcqpljsdfhsmzyf4ppbhbxmy",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mogj5rif2ip2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreieynn2hehxaz7qmi5sgvgjokadxxnjvlgbbcw5tk4p6fvumxvliau"
    },
    "mimeType": "image/jpeg",
    "size": 619149
  },
  "path": "/news/2026-06-pancreatic-cancer-strategy-kras-mutant.html",
  "publishedAt": "2026-06-16T15:00:08.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "Researchers at the University of Cologne's Center for Molecular Medicine Cologne (CMMC) have discovered a previously unknown mechanism that makes most pancreatic cancer cells susceptible to a form of programmed cell death. The team, led by Professor Dr. Silvia von Karstedt, showed that cancer cells with mutations in the KRAS gene develop a vulnerability that can be used to eliminate tumor cells in preclinical models. The findings open up new perspectives for treating pancreatic cancer. The study \"Oncogenic KRAS-Driven type I Interferon Signalling Primes Pancreatic Cancer for Necroptosis\" was published in the journal Nature Communications.",
  "title": "New pancreatic cancer strategy kills KRAS-mutant tumor cells and extends survival in mice"
}